MycoTechnology

MycoTechnology's 2024 decision to shut down FermentIQ plant protein is a candid admission that a large slice of its $277M-funded platform thesis did not pan out — capital was raised against a protein business that has now been discontinued, and investors who backed the broader "magic of mycelium" story are left with a narrower flavor-and-sweetener company. That refocus concentrates the bet on flavor modulation and sweeteners, which are competitive, incumbent-dominated markets: bitterness-blocking and sugar-reduction ingredients compete against Kerry, IFF, Givaudan, ADM, and a wave of other sweet-protein startups (Oobli, Amai, and others chasing brazzein/monellin), all courting the same reformulation budgets. B2B ingredient adoption is slow and reference-customer-dependent — GRAS status is necessary but not sufficient, and manufacturers move deliberately, so revenue from Zukora and the ClearIQ/ClearHT lines will ramp on multi-year timelines even in the best case. The last disclosed raise was 2022; a mid-2020s ingredient company that pivoted its core business and installed a new CEO in 2025 may need fresh capital in a funding environment far less generous than the one that produced the Series E. And sweet proteins face a practical wall: intense sweeteners often need bulking agents and mouthfeel fixes to actually replace sugar's functional role, so "2,500x sweeter" rarely translates cleanly into drop-in sugar replacement. The pivot may be correct, but it resets the growth clock on a company already a decade old.